Oncoimmunology

Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.

尽管肿瘤学家过去成功地利用了化疗和放疗方案，但他们可能无意中也利用了免疫系统识别肿瘤特异性抗原和控制癌症生长的能力。因此，免疫生物标志物对于癌症预后和预测化疗疗效变得越来越重要。人们积极支持将传统抗癌疗法与免疫疗法相结合。OncoImmunology 将欢迎涵盖肿瘤免疫学基础、转化和临床方面的高水平投稿，包括实体癌和血液癌、炎症以及先天性和获得性免疫反应。